Skip to main content
Premium Trial:

Request an Annual Quote

PGx Testing Firm Renaissance RX Expanding Operations in New Orleans

NEW YORK (GenomeWeb) – Pharmacogenetic testing firm Renaissance RX is expanding its operations in New Orleans with an $8 million investment, the company and Louisiana Economic Development announced on Tuesday.

The expansion is expected to create at least 425 new direct jobs and 407 new indirect jobs in the greater New Orleans area. Renaissance, founded in 2012, currently has 80 employees in the region and more than 800 across the country.

The firm will consolidate its business into a 30,000-square-foot building.

Louisiana is providing the company an incentive package that includes a $925,000 performance-based grant to defray the costs related to the expansion of its headquarters and laboratory. The grant will be paid in five annual installments of $185,000. Renaissance also will receive the workforce solutions of LED FastStart, a recruiting and training program, and is expected to participate in the state's Quality Jobs Program, which provides a cash rebate to companies that create well-paid jobs and promote economic development.

Renaissance RX uses gold-standard real-time PCR to provide pharmacogenetic testing, according to its website. It also has a toxicology business that uses liquid chromatography tandem mass spectrometry for quantitative urine drug testing.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.